Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240804 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL13911781 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL28391104 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 | |
| Ethylene SCHEMBL8557034 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL6984244 | 0.80 | MAPT (0.44) | SMN1; SMN2LMNAALDH1A1MAPTGAA | |
| SCHEMBL7696602 | 0.80 | MAPT (0.44) | SMN1; SMN2LMNAALDH1A1MAPTGAA | |
| SCHEMBL7594398 | 0.80 | MAPT (0.44) | SMN1; SMN2LMNAALDH1A1MAPTGAA | |
| SCHEMBL7594401 | 0.80 | MAPT (0.44) | SMN1; SMN2LMNAALDH1A1MAPTGAA | |
| Oxalic Acid SCHEMBL7591951 | 0.78 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1MAPTHTT | |
| Oxalic Acid SCHEMBL7590973 | 0.78 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1050530-B1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | SERVIER LAB (FR) | 2003-10-22 | — | — | EP | claimed |
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | RAULT SYLVAIN (FR) | 2002-04-11 | — | — | US | claimed |
| US-6323222-B1 | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | claimed |
| EP-1050530-A1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | ADIR ET COMPAGNIE (FR) | 2000-11-08 | — | — | EP | claimed |
| CN-1145612-C | New 1- aza-2-alkyl-6-aryl-cyclanes compound, its producing process and medical composition containing them | — | 2004-04-14 | — | — | CN | disclosed |
| EP-1050530-B1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | SERVIER LAB (FR) | 2003-10-22 | — | — | EP | disclosed |
| US-6451789-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS | LES LABORTOIRES SERVIER (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | RAULT SYLVAIN (FR) | 2002-04-11 | — | — | US | disclosed |
| US-6323222-B1 | COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| CN-1277194-A | New 1- aza-2-alkyl-6-aryl-cyclanes compound, its producing process and medical composition containing them | ADIR (FR) | 2000-12-20 | — | — | CN | disclosed |
| EP-1050530-A1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | ADIR ET COMPAGNIE (FR) | 2000-11-08 | — | — | EP | disclosed |
| EP-1050530-A1 | 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers | ADIR ET COMPAGNIE (FR) | 2000-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042413-A1 | 1-aza-2-alkyl-6-aryl-cycloalkanes | SULT2A1, GRIN2A, NR3C1 | SMN1; SMN2 682/4885MEN1 4318/4885KMT2A 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.